VOLUME 63   2002   NUMBER 2

CME Pretest 92

CME Posttest 172

Brainstorms

93 Antipsychotic Polypharmacy: Squandering Precious Resources? Stephen M. Stahl
[PDF]

Original Articles

95 What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression? Michael E. Thase
[Abstract] [PDF]

104 Obsessive-Compulsive Symptoms During Treatment With Olanzapine and Risperidone: A Prospective Study of 113 Patients With Recent-Onset Schizophrenia or Related DisordersLieuwe de Haan, M.D.; Nico Beuk, M.D.; Britt Hoogenboom, M.D.; Peter Dingemans, Ph.D.; and Don Linszen, M.D., Ph.D.
[Abstract] [PDF]

108 Comparison Between the Effects of Atypical and Traditional Antipsychotics on Work Status for Clients in a Psychiatric Rehabilitation Program. [CME] Piper S. Meyer, Gary R. Bond, Sandra L. Tunis, and Marion L. McCoy
[Abstract] [PDF]

117 No Weight Gain Among Elderly Schizophrenia Patients After 1 Year of Risperidone Treatment. Yoram Barak
[Abstract] [PDF]

120 Demographic and Clinical Characteristics of Individuals in a Bipolar Disorder Case Registry. [CME] David J. Kupfer, Ellen Frank, Victoria J. Grochocinski, Patricia A. Cluss, Patricia R. Houck, and Debra A. Stapf
[Abstract] [PDF]

126 Current Comorbidity of Psychiatric Disorders Among DSM-IV Major Depressive Disorder Patients in Psychiatric Care in the Vantaa Depression Study. Tarja K. Melartin, Heikki J. Rytsala, Ulla S. Leskela, Paula S. Lestela-Mielonen, T. Petteri Sokero, and Erkki T. Isometsa
[Abstract] [PDF]

135 Hepatotoxicity Associated With the New Antidepressants. Alfonso Carvajal Garcia-Pando, Javier Garcia del Pozo, Ana Sanchez Sanchez, Alfonso Velasco Martin, Ana Maria Rueda de Castro, and M. Isabel Lucena
[Abstract] [PDF]

138 Behavior Therapy for Obsessive-Compulsive Disorder Guided by a Computer or by a Clinician Compared With Relaxation as a Control. John H. Greist, Isaac M. Marks, Lee Baer, Kenneth A. Kobak, Keith W. Wenzel, M. Joyce Hirsch, Julia M. Mantle, and Cathryn M. Clary
[Abstract] [PDF]

146 Stabilization of Mood From Below Versus Above Baseline in Bipolar Disorder: A New Nomenclature. Terence A. Ketter and Joseph R. Calabrese
[Abstract] [PDF]

152 Predictors of Response to Pharmacotherapy in Social Anxiety Disorder: An Analysis of 3 Placebo-Controlled Paroxetine Trials. Dan J. Stein, Murray B. Stein, Cornelius D. Pitts, Rajinder Kumar, and Brian Hunter
[Abstract] [PDF]

156 Duration of Therapy and Health Care Costs of Fluoxetine, Paroxetine, and Sertraline in 6 Health Plans. Daniel Polsky, Peter Onesirosan, Mark S. Bauer, and Henry A. Glick
[Abstract] [PDF]

Letters to the Editor

165 Organic Hypomania Secondary to Sibutramine-Citalopram Interaction. Franco Benazzi
[PDF]

166 Risperidone-Induced Pisa Syndrome. Kenichi Harada, Nobuyuki Sasaki, Hiroshi Ikeda, Norihito Nakano, Hiroki Ozawa, and Toshikazu Saito
[PDF]

166 Interferon-Induced Depression Treated With Citalopram. Andy Farah
[PDF]

167 Clozapine and Tardive Dyskinesia. Richard Kumet and Marlene P. Freeman
[PDF]

168 Role of Receptor Binding Profiles in Antidepressant-Induced Sexual Dysfunction. Egon Michael Haberfellner
[PDF]

  • Reply by Angel L. Montejo

169 Olanzapine for the Treatment of Monosymptomatic Hypochondriacal Psychosis. Robert G. Fawcett
[PDF]

169 Retraction. Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone (J Clin Psychiatry 2000;61:909-911)
[PDF]

Book Reviews 170

NOW@Psychiatrist.com 174

Information for authors

see January 2002, pages 83-85 or our Web site at www.psychiatrist.com/author.htm